Sortina Pharma, a pioneer in developing next-generation therapies for cancer proudly announces its selection for the prestigious Brain Tumour Research Novel Therapeutics Accelerator (BTR-NTA) programme. This international initiative, launched by the Tessa Jowell Brain Cancer Mission (TJBCM) in partnership with Brain Tumour Research in 2023, provides independent expert guidance to de-risk and accelerate the development of novel brain tumour therapies.

Read More